A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question: whether BRAF V600E/K mutation status or previous BRAF inhibitor (BRAFi) therapy with or without a MEK inhibitor (MEKi) affects response to pembrolizumab (brand name Keytruda) in patients with advanced melanoma.

Proponents of making high-end health care services more accessible to people in Niagara County had reason to celebrate Thursday in downtown Niagara Falls.

The Tauber Bioinformatics Research Center at University of Haifa and Roswell Park Comprehensive Cancer Center in Buffalo, New York have launched a joint collaboration which will couple the expertise in cancer, genomics and biomedical research at Roswell Park and in bioinformatics at University of Haifa.

Two new studies led by Renuka Iyer, MD, Section Chief for Gastrointestinal Oncology at Roswell Park Comprehensive Cancer Center, highlight possible new treatment options for patients with neuroendocrine tumors (NETs) — a rare and hard-to-treat cancer.

Tackling challenging and hard-to-detect cancers of the reproductive system, the staff of the Department of Gynecologic Oncology at Roswell Park Comprehensive Cancer Center commit to being a pillar of evidence-based, patient-forward care each and every day. Highlighting this strength, Roswell Park Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, has announced the promotion of three staff members — Drs. Peter Frederick, Emese Zsiros and Melissa Moffitt — to leadership roles.